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Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical
benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies
investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary
endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing
antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus
tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression. Results. Eight studies (3,668 patients) were
included. Continuing antiangiogenic treatment beyond progression significantly improved PFS (HR 0.64; 95%-CI, 0.55–0.75) and
OS (HR 0.83; 95%-CI, 0.76–0.89). PFS was significantly improved in all subgroups with comparable HR. OS was improved in all
subgroups stratified by age, gender, and ECOG status.The rate of patients achieving at least stable disease was improved with anOR
of 2.25 (95%-CI, 1.41–3.58). Conclusions. This analysis shows a significant PFS and OS benefit as well as a benefit regarding disease
stabilization when using antiangiogenic drugs beyond progression in mCRC. Future studies should focus on the optimal sequence
of administering antiangiogenic drugs.
1. Introduction
First-line chemotherapy for metastatic colorectal cancer
(mCRC) is frequently combined with antiangiogenic agents,
namely, bevacizumab, a monoclonal antibody targeting vas-
cular endothelial growth factor (VEGF) A. This is based on
the results of several studies demonstrating a benefit in prog-
ression-free survival [1–4]. However, a statistically significant
prolongation of overall survival has only been observed in
one of these first-line studies [2] raising the question how
long the optimumduration of the use of antiangiogenic drugs
should be.
Prolonged duration of bevacizumab treatment until def-
initive progression has been shown to improve progression-
free survival in the phase 3 NO16966 trial which investigated
the addition of bevacizumab to oxaliplatin-based first-line
regimens [3]. Moreover, two observational studies showed
a correlation between the use of bevacizumab beyond pro-
gression and improved overall survival in advanced colorectal
cancer [5, 6]. Preclinical data strongly suggest that continued
antiangiogenic treatment beyond progression might provide
antitumor efficacy even in further lines of treatment [7, 8].
These observations led to the setup of clinical trials, which
investigated the use of bevacizumab beyond progression in
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patients who had undergone a bevacizumab-based first-line
treatment. Two trials (TML [9] and BEBYP [10, 11]), although
using different inclusion criteria and endpoints, unequivo-
cally demonstrated that the continued use of bevacizumab
beyond progression improved PFS (TML and BEBYP) and
overall survival (TML).
More recently, randomized trials investigated other drugs
with antiangiogenic properties in second and further lines
of treatment in patients with metastatic colorectal cancer
after pretreatment with bevacizumab-based regimens. For
instance, the phase-3 VELOUR trial investigated the addition
of aflibercept (a fusion protein trapping VEGF-A, VEGF-
B, and placental growth factor [PlGF]) in combination
with 5-fluorouracil and irinotecan (FOLFIRI) treatment in
patients who had been pretreated with oxaliplatin-based
regimens [12]. It was demonstrated that the addition of
aflibercept improved progression-free and overall survival.
Notably, this also held true for the patientswith bevacizumab-
pretreatment [13].The concept of continued use of antiangio-
genic drugs has also been demonstrated in the CORRECT
study and the CONCUR study in which treatment with
regorafenib—a multikinase inhibitor targeting among others
VEGF-receptor 2—was superior to best supportive care in
patients who had been pretreatedwith all active drugs includ-
ing bevacizumab [14, 15]. Taken together, data from recent
studies suggest that prolonged duration of antiangiogenic
treatment might be associated with improved outcome in
patients with metastatic colorectal cancer.
In the present meta-analysis we sought to investigate the
concept of treatment with antiangiogenic drugs in multiple
lines beyond progression by analyzing aggregate data of
randomized trials. Special emphasis was given on describing
potential improvements of progression-free and overall sur-
vival related to specific subgroups including KRAS wildtype
patients.
2. Patients and Methods
2.1. Objectives of Meta-Analysis and Eligibility Criteria. Pri-
mary objective of the present analysis was to investigate
progression-free survival (PFS) and overall survival (OS)
in patients with metastatic colorectal cancer who had been
pretreated with an antiangiogenic treatment and underwent
antiangiogenic treatment beyond progression.
Secondary objectives were to assess the effects of the
continued or repeated antiangiogenic treatment in subgroups
(stratified by age, sex, ECOG status, and tumor KRAS
mutational status) and in studies using anti-VEGF treatment
(i.e., bevacizumab and aflibercept) versus tyrosine kinase
inhibitors (TKI).Moreover, we investigated the response rates
(i.e., the rate of evaluable patients achieving complete or
partial remissions) and the rate of “tumor stabilization,” that
is, the rate of evaluable patients without primary progression
while receiving treatment.
Only randomized phase II and III trials were included in
the current meta-analysis.The inclusion of subgroups of ran-
domized trials was allowed provided sufficient information
was given in the trial reports.Only studies performedwith the
approval of an appropriate ethics committee and conducted
in compliance with the declaration of Helsinki were included
in this meta-analysis.
Antiangiogenic treatment was defined as the use of drugs
targeting at least one important angiogenic pathway, for
instance, monoclonal antibodies targeting VEGF or VEGF-
receptors, or (multi)TKI targeting angiogenic pathways.
2.2. Information Sources, Search Strategy, and Study Selec-
tion. Searches in PubMed and proceedings of international
meetingswere conducted to identify studieswith information
relevant for the current analysis.
Eligible studies were phase II or III, randomized, con-
trolled trials comparing (i) antiangiogenic drugs in com-
bination with either active treatment (i.e., chemotherapy)
or placebo with (ii) active treatment or placebo alone in
patients who had previously been treated with antiangiogenic
drugs for metastatic colorectal cancer. We used MeSH and
full-text search terms for metastatic colorectal cancer and
molecular targeted therapies, limiting our results to English
language articles published in PubMed between January 1,
2007, and October 11, 2015. For PubMed, the search was
((((“molecular targeted therapy” [All Fields]OR (“molecular”
[All Fields] AND “targeted” [All Fields]) AND (“therapy”
[All Fields] OR “therapies” [All Fields]) AND (“colorectal
neoplasms” [All Fields] OR “colorectal cancer” [All Fields])
OR (“colorectal” [All Fields] AND “cancer” [All Fields])
AND(“randomized” [All Fields]OR “randomized study” [All
Fields]) AND English [lang])))).
In addition to computerized search, references of
retrieved papers were also screened for missing trials.
To minimize publication bias we conducted a manual
search of conference abstracts. For conferences, the search
was “colorectal cancer” or “advanced colorectal cancer”,
manually limited to abstracts on targeted therapies. The
proceedings of the following meetings were examined for
presented abstracts limiting the search to the years 2007–
2016: (i) American Society of Clinical Oncology (ASCO)
annual meetings; (ii) ASCO Gastrointestinal Cancer Sympo-
sium; (iii) European Society for Medical Oncology (EMSO)
and European multidisciplinary cancer congress (ECCO)
meetings; (iv) World Congress on Gastrointestinal Cancer.
Two independent reviewers (RDH, UR, or UH) assessed title,
keywords, and abstracts of retrieved studies. If studies met
the inclusion criteria, they assessed full texts and mutually
decided on inclusion.
2.3. Data Collection. Data extraction was conducted inde-
pendently by three investigators (RDH, UR, and UH) in
accordancewith the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidance [19]. For
each study the following information was extracted: publi-
cation or presentation date, first author’s last name, sample
size/sample size of subgroup of interest, primary endpoints,
information pertaining to study design, PFS, andOS aswell as
response definition, regimens used, line of treatment, number
of outcome events, data on PFS, OS, response to treatment,
and data of subgroups of interest.
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Table 1: Overview of studies included in meta-analysis.
Study First author/year Investigationaltreatment Control treatment Primary endpoint
Number of
patients (ITT)
(active/control)
TML Bennouna 2012 [9]
Chemotherapy
(oxaliplatin or
irinotecan based)
plus bevacizumab
Chemotherapy
(oxaliplatin or
irinotecan based)
alone
OS 819 (409/410)
CORRECT Grothey 2013 [14] Regorafenib Placebo OS 760 (505/255)
BEBYP Masi 2013 [10]
Chemotherapy
(FOLFIRI,
mFOLFOX)
plus bevacizumab
Chemotherapy
(FOLFIRI,
mFOLFOX) alone
PFS 184 (92/92)
VELOUR subgroup Allegra 2012 [13] FOLFIRI plusaflibercept FOLFIRI OS 373 (186/187)
AGITG subgroup Siu 2013 [16] Cetuximab plusbrivanib Cetuximab OS 310 (152/158)
FOSCO Hoehler 2013 [17] FOLFOX/FOLFIRIplus sorafenib
FOLFOX/FOLFIRI
plus placebo PFS 69 (32/37)
RAISE Tabernero 2015 [18] FOLFIRI plusramucirumab FOLFIRI plus placebo PFS 1072 (536/536)
CONCUR Li 2015 [15] Regorafenib Placebo OS 81
2.4. Synthesis of Results, Statistical Methods, and Analyses.
The impact of antiangiogenic treatment on overall survival
(OS) and progression-free survival (PFS) was measured in
terms of the hazard ratio (HR). In all studies included in
this meta-analysis, the HR was calculated as ratio of the
active therapy divided by the hazard of the control group.
Therefore, a HR lower than 1 indicates a benefit of the active
treatment, whereas a HR higher than 1 indicates a higher risk
of death or progression of the active treatment, respectively.
The estimates of the HR were extracted directly from the
publications and variance of the estimates was calculated
from published confidence intervals of the HR. For the TML
study, unstratified as well as stratified HRs were reported. As
the unstratified analysiswas the primary analysis of this study,
the unstratified estimates were included in the meta-analysis.
Heterogeneity of the individual HRs was tested using
Cochran’s 𝑄 statistic [19]. If heterogeneity was not detected
at the 10% significance level, the fixed effects model was
used. If the test for heterogeneity was significant, the overall
HR was calculated using the random effects model [20].
Heterogeneity was quantified by 𝐼2 coefficient measuring the
percentage of total variation across studies that is due to
heterogeneity rather than by chance.
Meta-analysis of the remission, progression, and rates
of “tumor stabilization” was performed using the same
statistical methods described above. In the remission analysis
and in the progression analysis patients with unknown status
were counted as progressive. Finally, in the “prevention of
progression” (POP) analysis patients with unknown status
were excluded.
ML-estimates of the odds ratio (OR) were determined
from reported contingency tables and the within-trial vari-
ance was computed from the inverse of the matrix of second
derivatives of the log-likelihood (Woolf ’s formula).
3. Results
3.1. Selected Trials. TheMedline search was done on June 15,
2016. It resulted in 3,252 articles.Hand-searches of conference
proceedings were conducted including all conferences until
June 2016.
Based on the criteria defined above the following eight
studies were selected for inclusion into the current meta-
analysis (PRISMA diagram; cf. Figure 1): TML trial [9],
BEBYP trial [10, 11], subgroup of VELOUR study [12],
CORRECT trial [14], subgroup of AGITG CO.20 trial [16],
a subgroup of patients treated within a randomized phase
II trial (FOSCO) investigating the addition of sorafenib to
second-line chemotherapy [17], subgroups of the CONCUR
study [15], and the RAISE study [18].
Trial characteristics are depicted in Table 1. All trials were
evaluable for PFS and OS.
Table 2 shows the number of patients evaluable from
respective trials for the determination of primary and sec-
ondary outcome parameters.
3.2. Combined Analysis: Primary Outcomes—Progression-
Free and Overall Survival. The use of antiangiogenic drugs
beyond progression improved progression-free survival and
overall survival over control (i.e., best supportive care or
active treatment alone). The hazard ratio for overall survival
(𝑛 = 3,668) was 0.83 (95%-CI, 0.76–0.89); (Figure 2).The test
for heterogeneity was significant (𝑝 = 0.010; 𝐼2 = 40%). PFS
was improved (𝑛 = 3,668) with a HR of 0.64 (95%-CI, 0.55–
0.75); test for heterogeneity: 𝑝 < 0.001; 𝐼2 = 74%; (Figure 3).
3.3. Combined Analysis: Secondary Outcomes—Subgroup
Analyses of Progression-Free and Overall Survival. The results
of the subgroup analyses for PFS and OS according to sex,
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Figure 1: PRISMA diagram.
TML
CORRECT
BEBYP
VELOUR
AGITG
FOSCO
RAISE
CONCUR1
CONCUR2
Overall
0.5 1 1.5 2 3 4
Hazard ratio and 95%-CI n HR
819
760
184
373
310
69
1072
45
36
3668
0.81 (0.69–0.94)
0.77 (0.64–0.94)
0.77 (0.56–1.06)
0.86 (0.67–1.10)
0.80 (0.62–1.05)
2.30 (1.23–4.29)
0.84 (0.73–0.98)
0.99 (0.48–2.03)
0.48 (0.22–1.08)
0.83 (0.76–0.89)
Favours active Favours control
Figure 2: Meta-analysis for overall survival. CI: confidence interval; HR: hazard ratio.
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Overall
Figure 3: Meta-analysis for progression-free survival. CI: Confidence interval; HR: hazard ratio.
Table 2: Overview of number of studies and patients available for primary and secondary analyses.
Progression-free survival Overall survival
Primary endpoint 𝑛 = 8 trials (𝑛 = 3,688 pts) 𝑛 = 8 trials (𝑛 = 3,668 pts)
Secondary endpoint: PFS/OS subgroup analyses
Gender (male/female) 𝑛 = 4 trials (𝑛 = 3,017 pts) 𝑛 = 3 trials (𝑛 = 2,651 pts)
Age (cut-off 65 years) 𝑛 = 4 trials (𝑛 = 2,835 pts) 𝑛 = 3 trials (𝑛 = 2,651 pts)
ECOG status (0 versus ≥1) 𝑛 = 4 trials (𝑛 = 2,825 pts) 𝑛 = 3 trials (𝑛 = 2,641 pts)
KRAS status (WT/MUT) 𝑛 = 4 trials (𝑛 = 2,545 pts) 𝑛 = 3 trials (𝑛 = 2,417 pts)
Secondary endpoint: remission/progression analyses
Remission rate 𝑛 = 5 trials (𝑛 = 3,199 pts)
Progression rate 𝑛 = 4 trials (𝑛 = 2,826 pts)
Prevention of progression rate 𝑛 = 4 trials (𝑛 = 2,652 pts)
age, ECOG status, and KRAS status (WT versus MUT) are
given in Table 3 (PFS) and Table 4 (OS) and in Supplementary
Figures S1–S8 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9189483. In all subgroup anal-
yses (age, using a cut-off of 65 years, ECOG performance
status, gender, and tumor KRAS mutational status) the
use of antiangiogenic drugs beyond progression improved
PFS with comparable hazard ratios in both dichotomized
groups, respectively. Similarly, overall survival results are
comparable for dichotomized subgroups regarding age and
ECOG performance status. However, the benefit of using
antiangiogenic drugs beyond progression regarding OS was
weaker in the subgroup of women (𝑛 = 1,047) with a HR
of 0.81 (95%-CI, 0.70–0.94) and absent in patients bearing a
tumor with KRAS mutation (𝑛 = 1,260) with a HR of 0.89;
95%-CI, 0.78–1.02.
PFS was improved both in studies using mAB targeting
the VEGF-axis (𝑛 = 2,448), HR 0.73 (95%-CI, 0.67–0.79)
(no heterogeneity was identified 𝑝 = 0.37, 𝐼2 = 0%), and in
studies using TKI (𝑛 = 1,220), HR 0.55 (95%-CI, 0.38–0.78)
(test for heterogeneity 𝑝 = 0.010, 𝐼2 = 70.%) (Supplementary
Figure S9). The pooled HR for OS regarding trials investigat-
ing monoclonal antibodies (mAB) targeting the VEGF-axis
(TML, BEBYP, VELOUR subgroup, and RAISE; 𝑛 = 2448)
was 0.83 (95%-CI, 0.75–0.91) (test for heterogeneity 𝑝 = 0.93,
𝐼
2 =0%) and the pooledHR forOS in studies investigating the
use of TKI beyond progression (CORRECT, FOSCO, AGITG
subgroup, and CONCUR subgroups; 𝑛 = 1220) was 0.92
(95%-CI, 0.59–1.42) (test for heterogeneity 𝑝 = 0.011, 𝐼2 =
69.%) (Supplementary Figure S10).
The use of antiangiogenic drugs beyond progression did
not increase response rates (𝑛 = 5 trials included in meta-
analysis with a total of 𝑛 = 3,199 patients) (Table 5 and
Figure 4). The odds ratio (OR) was 1.18 (95%-CI, 0.94–1.49).
In contrast, progression rate was decreased (𝑛 = 4 trials
included in meta-analysis with a total of 𝑛 = 2,826 patients)
(Table 6 and Figure 5).The odds ratio (OR) was 0.51 (95%-CI,
0.31–0.82). Finally, the rate of evaluable patients achieving at
least stable disease (𝑛 = 4 trials reporting data with a total of
𝑛 = 2,652 patients) was improved with an OR of 2.25 (95%-
CI, 1.41–3.58) (Table 7 and Figure 6).
4. Discussion
Using aggregate data from eight randomized trials we found
a clinically relevant and significant improvement of PFS and
OS for the use of antiangiogenic drugs beyond progression
with a cumulative hazard ratio of 0.64 for PFS and 0.83 for
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Table 3: Results of subgroup analyses for progression-free survival.
Subgroup 𝑛 HR 95% CI Test of heterogeneity
𝑄-value
Test of heterogeneity
𝑝 value 𝐼
2 coefficient
Age
<65 years 1670 0.62 0.47–0.82 𝑄 = 27.7950 𝑝 < 0.001 89.21%
≥65 years 1165 0.74 0.66–0.84 𝑄 = 2.1756 𝑝 = 0.54 0%
Sex
Male 1907 0.68 0.54–0.84 𝑄 = 13.2772 𝑝 = 0.004 77.40%
Female 1110 0.66 0.49–0.89 𝑄 = 15.3943 𝑝 = 0.002 80.51%
ECOG status
0 1440 0.61 0.48–0.80 𝑄 = 16.3356 𝑝 < 0.001 81.64%
≥1 1385 0.73 0.60–0.88 𝑄 = 6.5342 𝑝 = 0.088 54.09%
KRAS status
Wildtype 1219 0.60 0.47–0.76 𝑄 = 14.7202 𝑝 = 0.02 76.62%
Mutation 1326 0.66 0.53–0.83 𝑄 = 15.5233 𝑝 = 0.001 80.67%
Table 4: Results of subgroup analyses for overall survival.
Subgroup 𝑛 HR 95% CI Test of heterogeneity
𝑄-value
Test of heterogeneity
𝑝 value 𝐼
2 coefficient
Age
<65 years 1578 0.80 0.71–0.90 𝑄 = 1.2902 𝑝 = 0.52 0%
≥65 years 1073 0.84 0.73–0.97 𝑄 = 0.0354 𝑝 = 0.98 0%
Sex
Male 1604 0.82 0.73–0.92 𝑄 = 3.8902 𝑝 = 0.14 48.59%
Female 1047 0.81 0.70–0.94 𝑄 = 3.4071 𝑝 = 0.18 41.30%
ECOG status
0 1290 0.76 0.67–0.88 𝑄 = 0.9274 𝑝 = 0.63 0%
≥1 1351 0.86 0.76–0.97 𝑄 = 0.7502 𝑝 = 0.69 0%
KRAS status
Wildtype 1157 0.74 0.64–0.85 𝑄 = 1.7867 𝑝 = 0.41 0%
Mutation 1260 0.89 0.78–1.02 𝑄 = 0.09216 𝑝 = 0.95 0%
Table 5: Analysis of response rate. Number of patients achieving tumor remissions according to treatment.
Study name Active treatment Control OR 95%-CI
Remission No remission Remission No remission
TML 22 382 16 390 1.40 [0.73–2.71]
CORRECT 5 500 1 254 2.54 [0.30–21.86]
BEBYP 19 73 16 76 1.24 [0.59–2.59]
VELOUR 22 164 16 171 1.43 [0.73–2.83]
RAISE 72 464 67 469 1.09 [0.76–1.55]
Overall Test of heterogeneity: 𝑄 = 1.2927, 𝑝 = 0.86, 𝐼2 = 0% 1.18 [0.94–1.49]
Table 6: Analysis of tumor progression. Number of patients experiencing tumor progression according to treatment.
Study name Active treatment Control OR 95%-CI
Progression No progression Progression No progression
TML 129 275 186 220 0.55 [0.42–0.74]
CORRECT 298 207 217 38 0.25 [0.17–0.37]
BEBYP 28 64 39 53 0.59 [0.32–1.09]
RAISE 139 397 167 369 0.77 [0.59–1.01]
Overall Test of heterogeneity: 𝑄 = 21.9488, 𝑝 < 0.001, 𝐼2 = 86.33%→ random effect model 0.51 [0.31–0.82]
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Table 7: Analysis of tumor stabilization rate. Number of patients experiencing at least stable disease according to treatment.
Study name Active treatment Control OR 95%-CI
No progression Progression No progression Progression
TML 275 87 220 142 2.04 [1.48–2.81]
CORRECT 221 284 38 217 4.44 [3.02–6.54]
BEBYP 64 27 53 37 1.65 [0.89–3.06]
RAISE 397 87 369 134 1.66 [1.22–2.25]
Overall Test of heterogeneity: 𝑄 = 17.03610, 𝑝 < 0.001, 𝐼2 = 82.39%→ random effect model 2.25 [1.41–3.58]
TML
CORRECT
BEBYP
VELOUR
RAISE
Favours activeFavours control
n OR
810
760
184
373
1072
3199
1.40 (0.73–2.71)
2.54 (0.30–21.9)
1.24 (0.59–2.59)
1.43 (0.73–2.83)
1.09 (0.76–1.55)
1.18 (0.94–1.49)
2.5 5 10 15 22.5
Odds ratio and 95%-CI
Overall
Figure 4: Meta-analysis of remission rate. CI: confidence interval; OR: odds ratio.
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Figure 5: Meta-analysis of progression rate. CI: confidence interval; OR: odds ratio.
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Figure 6: Meta-analysis of prevention of progression rate. CI: confidence interval; OR: odds ratio.
OS. The test for heterogeneity of study results was significant
for both OS and PFS.The latter was mainly influenced by the
results of the FOSCO trial for PFS and OS and additionally of
the CORRECT trial for PFS.While the relative risk reduction
for PFS was 35%, the survival benefit was 17% (HR 0.83). The
main outlier in the OS analysis was the small FOSCO trial,
which, however, had a relatively strong impact on the hazard
ratio. Excluding FOSCO from the meta-analysis would result
in an even lower hazard ratio underlining a significant benefit
of continuing antiangiogenic drugs after first progression.
FOSCO is one of a couple of studies investigating the addition
ofmultityrosine kinase inhibitors to a chemotherapy doublet.
All of these trials—regardless of the treatment setting, that
is, 1st or 2nd line—have resulted in negative study results
mainly caused by increased toxicity, decreased dose inten-
sity, and compromised quality of life (e.g., CONFIRM or
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HORIZON studies). Thus, with the exception of FOSCO we
found relatively homogeneous results regarding the patient-
relevant endpoint of overall survival with a relative risk
reduction for death of approximately 20% for continuation of
antiangiogenic treatment beyond progression. Interestingly,
the effects of different concepts (i.e., continuing bevacizumab
beyond progression or switching to other antiangiogenic
agents, for instance, aflibercept or ramucirumab) resulted
in comparable hazard ratios for OS ranging between 0.77
and 0.86. Therefore, either approach might be considered
for patients progressing after bevacizumab-based first-line
therapy and the decision should be made in light of toxicity,
patient preference, and drug approval status.
We also investigated the effects of continued antiangio-
genic treatment in subgroups. The decision to carry out
analyses stratified by age, ECOG status, and gender as well as
KRASmutational status was mainly taken due to the fact that
other subgroups of interest (for instance, liver onlymetastases
and time interval between last bevacizumab treatment) have
not been reported by a sufficiently high number of trials to
enable a meta-analysis. In all subgroup analyses an improved
PFS was found. The HR of the respective dichotomized
groups (age <65 versus ≥65 years; women versusmen, ECOG
0 versus ≥1, and KRASwildtype versus KRASmutation) were
comparable. Similarly, overall survival results are comparable
for dichotomized subgroups regarding age and ECOG per-
formance status. However, the effect of using antiangiogenic
drugs beyond progression regarding OS was weaker in the
subgroup of women (𝑛 = 1,047) with a HR of 0.81 (95%-CI,
0.70–0.94) andnot statistically significant for patients bearing
a tumor with KRAS mutation (𝑛 = 1,260) with a HR of 0.89
(95%-CI, 0.78–1.02).The latter finding is difficult to interpret.
However, a significant PFS benefit was demonstrated for
both tumors with KRAS wildtype and KRAS mutations (HR
0.60 and 0.66, resp.) which suggests that patients with RAS
mutations should not be excluded from continued treatment
with antiangiogenic agents.
No improvement in response rates was seen; however,
the rate of progression was decreased. Additionally, we
analyzed the potential to prevent tumor progression (defined
as the number of patients with evaluable remission status
achieving at least stable disease). In this analysis a clinically
relevant benefit for the use of antiangiogenic drugs beyond
progression was found. This is in line with earlier findings
from the first-line setting, indicating that the activity of beva-
cizumab in combination with chemotherapy with respect to
a prolongation of PFS is predominantly driven by disease
stabilization [21].
In all, the current meta-analysis demonstrates the useful-
ness of continued antiangiogenic drugs beyond progression
regarding their potential to improve PFS andOS in a clinically
meaningful manner. The benefit was seen in the subgroups
stratified by age, gender, and ECOG performance status.
Limitations of the current analysis are that no individual
patient data were used and toxicity could not be assessed.
Furthermore, although the antiangiogenic activity of the
drugs included in the analysis may differ, we decided to
include studies with multityrosine kinase inhibitors such
as regorafenib as well, because these drugs are believed to
exert their main activity via antiangiogenic mechanisms.
Moreover, the size of some subgroups assessed in our analyses
was small. Therefore, statistical power of single analyses
might have been too low to show a significant difference in
these subgroups, namely, women and KRAS-mutant tumors.
Our meta-analysis, synthesizing data from several trials,
indicates that using antiangiogenic drugs beyond and after
progression can meanwhile be regarded as an established
strategy in the treatment of patientswithmetastatic colorectal
cancer. Future research should especially focus on the optimal
sequence of using these antiangiogenic drugs, for instance,
the timing of the switch from bevacizumab to broader active
drugs such as aflibercept or regorafenib. Clearly, in this aspect
biomarkers will be needed to elucidate if inhibition of alter-
native angiogenic pathways or additional tyrosine kinases
would be required for continued antiangiogenic activity or if
the patient could remain on bevacizumab treatment.
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